Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial
Journal of Clinical Oncology · 20.12.2025 · 43 (36) · 3799-3811
DOI: 10.1200/jco-25-01957 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.12.2025. Verfasst von Lihua E Budde und 27 weiteren Autor:innen. Beteiligte Einrichtung: City of Hope, Duarte, CA. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Lymphoma, Large B-Cell, Diffuse, Immunoconjugates, Antibodies, Bispecific. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE Prognosis for patients with refractory/relapsed large B-cell lymphoma (LBCL) considered ineligible for curative-intent therapy is poor. The combination of mosunetuzumab, a T-cell–engaging bispecific antibody, and polatuzumab vedotin, an antibody-drug conjugate (Mosun-Pola), represents a novel fixed-duration outpatient therapy. METHODS In the phase III SUNMO trial, patients with refractory/relapsed LBCL who were ineligible for autologous stem-cell transplant were randomly assigned (2:1) to receive Mosun-Pola or rituximab, gemcitabine, and oxaliplatin (R-GemOx). Dual primary end points were centrally assessed overall response rate (ORR) and progression-free survival (PFS). Overall survival was a key secondary end point. RESULTS A total of 208 patients were randomly assigned to receive Mosun-Pola (n = 138) or R-GemOx (n = 70). At a median follow-up of 23.2 months, the primary analysis of SUNMO demonstrated that the median PFS was significantly longer with Mosun-Pola than with R-GemOx (11.5 months [95% CI, 5.6 to 18] v 3.8 months [95% CI, 2.9 to 4.1]; hazard ratio for progression or death, 0.41 [95% CI, 0.3 to 0.6]; P < .0001). ORR was significantly greater with Mosun-Pola versus R-GemOx (70% v 40%; P < .0001), with complete response rates of 51% and 24%, respectively. In the Mosun-Pola group, the rate of grade ≥2 cytokine release syndrome (CRS) and usage of tocilizumab occurred in
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- City of Hope, Duarte, CA.
- Tianjin Medical University Cancer Institute, Tianjin, China.
- Samsung Medical Center, Seoul, Republic of Korea.
- Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
- Instituto D'Or de Pesquisa e Ensino, São Paulo, Brazil.
- Chiang Mai University, Chiang Mai, Thailand.
ORCID-Profile: Lihua E Budde, Won-Seog Kim, Eduardo M Rego, Lalita Norasetthada, Young-Woo Jeon, Danielle Leão Cordeiro de Farias, Hideki Goto, Adam J Olszewski, Nikesh Shah, Bei Hu, Shen Yin, Iris To, Antonia Kwan, Connie L Batlevi, Michael C Wei, Jason Westin
Zitieren
APA
Budde, L. E., Zhang, H., Kim, W. S., Maruyama, D., Rego, E. M., Norasetthada, L., Hong, H., Ozcan, M., Jeon, Y. W., Leão Cordeiro de Farias, D., Fogliatto, L. M., Pavlovsky, A., Goto, H., Olszewski, A. J., Shah, N., Hu, B., Yin, S., Wu, H., To, I., …, & Westin, J. (2025). Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial. Journal of Clinical Oncology, 43(36), 3799-3811. https://doi.org/10.1200/jco-25-01957
Vancouver
Budde LE, Zhang H, Kim WS, Maruyama D, Rego EM, Norasetthada L, et al. Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial. Journal of Clinical Oncology. 2025;43(36):3799-3811. doi:10.1200/jco-25-01957
BibTeX
@article{Budde2025,
author = {Budde, Lihua E and Zhang, Huilai and Kim, Won-Seog and Maruyama, Dai and Rego, Eduardo M and Norasetthada, Lalita and Hong, Huangming and Ozcan, Muhit and Jeon, Young-Woo and Leão Cordeiro de Farias, Danielle and Fogliatto, Laura Maria and Pavlovsky, Astrid and Goto, Hideki and Olszewski, Adam J and Shah, Nikesh and Hu, Bei and Yin, Shen and Wu, Hao and To, Iris and Ead, Wahib S and Ashby, Joan and Janousek, Martin and Pham, Song and Wang, Jue and Kwan, Antonia and Batlevi, Connie L and Wei, Michael C and Westin, Jason},
title = {Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial},
journal = {Journal of Clinical Oncology},
year = {2025},
volume = {43},
number = {36},
pages = {3799--3811},
doi = {10.1200/jco-25-01957}
}
EUVIMED